Lupin Limited

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

To put India and the world at the forefront of the global pharmaceutical industry by providing meaningful and innovative healthcare solutions for all of the stakeholders in the healthcare value chain.

To create global health care through breakthroughs in technology, by partnering with research and academic organizations and leveraging a diverse portfolio of therapeutic and specialty products.

Lupin Ltd has earned many awards over the years, including numerous awards from CII, Good Pharmaceutical Management Awards , India Pharma Awards, Drug Today- Pharma Leaders Survey, and many other prestigious awards.